Research article · 15 Jul 2025
Research articlePublished 31 Mar 2022
Recurrence of acute migraine following ubrogepant and diclofenac buffered solution combination therapy- An observational study
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Objective: To analyze the need for a repeat dose following administration of a single fixed combination dose of ubrogepant and diclofenac potassium buffered solution for an acute migraine attack. Background: A relapse after pain freedom/relief from a migraine abortive is an acute treatment failure. Reduction of acute disability and prevention of chronification is dependent on effective, rapid, complete abortive treatment without adverse effects. Methods: Ubrogepant 100 mg tabs and diclofenac potassium buffered solution 50 mg powder (UBR/DICb) are both FDA approved for acute migraine therapy. Twenty-three subjects, 22 female, 1 male with episodic or chronic migraine with and without aura were instructed take both agents within 15 minutes of the migraine attack. Pain freedom and pain relief at 2 hrs were recorded and need for repeat dose for relapse was the primary efficacy outcome measure for this study. Relief of most bothersome symptoms (MBS)-nausea, photophobia, phonophobia, and adverse effects were also recorded. Observation for need for repeat dosing was extended to 24 hrs. Preventives were permitted. Results: Two hours following a single fixed dose of UBR/DICb, 96% of the enrolled study patients were pain free or obtained pain relief with no need for a second dose, and 4% did not respond. Of the 23 patients enrolled in the study, 87% experienced pain freedom with no need for re-dosing , (CI 95% (0.7, 1.0), and 9% had pain relief with no need for re-dosing (CI 95% (-0.02, 0.2), and 4% had no pain relief or freedom and no response to re-dosing (CI 95% (-0.04, 0.12)). Reduction in MBS paralleled pain reduction in our study cohort. None of the responders required a second dose of UBR/DICb for the next 24 hrs. Conclusion: At 2 hours, all pain free and pain relief responders to single dose combination ubrogepant and diclofenac buffered solution did not need a repeat dose. Sustained efficacy without re-dosing necessity is maintained for 24 hrs. Single dose combination ubrelvy/ diclofenac buffered solution resulted in a significant reduction in need for a second dose than ubrelvy alone from previously published studies. This small observational study will need to be validated in placebo controlled larger studies.
Keywords
Subjects
Neuroscience & NeurologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Neurology and Neuroscience.
Research article · 15 Jul 2025
Diffuse Intrinsic Pontine Glioma: Unusually Long Survival of 28 Patients (From 3 Years to Over 29 Years) in Phase 2 Studies with Antineoplastons A10 and AS2-1
Short communication · 24 Jun 2025
The Role of High-Pressure Balloon Angioplasty in Treating Intracranial Atherosclerosis
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Neurology and Neuroscience
- SubjectNeuroscience & Neurology
- BylineArticles whose byline prints “James A Charles”
- BylineArticles whose byline prints “Nicole Suttora”
